AT Sens said that it has signed a contract with Al Dabbous Medical Company, a Kuwait-based medical device distributor, to export AT-Patch, a continuous, long-term use electrocardiogram (ECG) device.

AT Sens will export $2.4 million worth of its continuous electrocardiogram device, AT Patch, to Kuwait.
AT Sens will export $2.4 million worth of its continuous electrocardiogram device, AT Patch, to Kuwait.

Under the accord, AT Sens will export about 3 billion won ($2.4 million) worth of AT-Patch to Al Dabbous Medical Company, with official sales taking place as soon as the company completes local license registration in June.

“Using this contract as a stepping stone, we will accelerate AT Patch’s entry into the Middle East market following Europe and Japan,” AT Sens CEO Jung Jong-wook said. “As the sales of AT-Patch to Korean hospitals have been expanding after receiving reimbursement, we will do our best to contribute to developing early diagnosis and preventive treatment of heart disease, both at home and abroad.”

AT Patch is the first long-term continuous ECG device that patients can use continuously for up to 14 days. The company has three models -- ATP-C70 (7 days), ATP-C120 (11 days), and ATP-C130 (14 days) – depending on the period.

AT-Patch has acquired Conformite Europeenne (CE) medical device certification and completed the registration of medical devices with the Medical and Healthcare Products Regulatory Agency (MHRA) in the U.K.

The company has signed supply contracts for AT-Patch with 11 countries, including Kuwait and Germany, and is discussing with 13 countries, including the U.S., UK, and Switzerland.

Copyright © KBR Unauthorized reproduction, redistribution prohibited